Premium Structural Biology & Lead Discovery Services

SARomics Biostructures provides premium structural biology and structure-based drug discovery services to the biotech industry and academic institutions. We have many years of experience and proven excellence in protein production, biophysical characterization and crystallization, protein X-ray crystallography and BioNMR spectroscopy, fragment screening, and fragment-based lead generation.

Please visit the "about" pages for additional company information. For details on the experimental methods, visit our technology platform overview. For the latest blog posts see here.

For the details of our services, follow the links below. You may also contact us directly for a company presentation and project discussion.
You may also search here for the protein of interest:
Our protein X-ray crystallography services provide protein crystallization and X-ray structure determination, FastLane™ Premium and FastLane™ standard libraries of verified drug targets (off-the-shelf structures), protein production and custom gene-to-structure and protein-ligand complex X-ray structure determination.
We provide a broad range of custom protein NMR (BioNMR) spectroscopy services that include peptide, protein, protein-ligand & protein-protein complex NMR assignment and 3D structure determination, NMR fragment screening using 1D or 2D NMR, epitope mapping and dissociation constant (Kd) determinations for compounds.
Antibody and antibody-antigen complex crystallization and high resolution X-ray structure determination, BioNMR and crystallographic characterization of higher order structure (HOS) of biosimilars, comparison with originator antibody and formulation optimization, biophysical characterization of antibodies and biosimilars in solution.
High throughput (2000-3000 cmpds/week), robust and accurate (validated against NMR and X-ray) fragment screening using weak-affinity chromatography (WAC™), which also includes binding assay and measurement of fragment affinity to immobilized protein - all in one experiment!
Computation chemistry is an integral part of our structure-based lead discovery services. We use state-of-the-art computational chemistry software and have gathered extensive experience in all aspects of computational chemistry, including:
  • Virtual screening services
  • Pharmacophore and shape-based virtual screening
  • Ligand-based drug design, etc.
Our integrated lead discovery and structure-based drug design (SBDD) services include fragment screening, hit identification, hit-to-lead, and lead optimization. In collaboration with our in-house partner, Read Glead Discovery, we offer structure-based hit expansion, hit-to-lead, and lead optimization services.

State-of-the-art structural biology technology platform

Our technology services platform is equipped with state-of-the-art instrumentation for all aspects of structural biology, including protein production, robotic nanoliter-scale crystallization screening and optimization of conditions for crystal growth, and crystallization drop imaging. For X-ray crystallographic data collection, we use the MAX IV synchrotron radiation facility (image above), located a couple of kilometers from our labs in Lund. Alternatively, we send the crystals to other European synchrotrons. We collect X-ray data approximately every second week.

We have access to high-quality, cutting-edge instrumentation for NMR spectroscopy services. We provide
de novo NMR protein structure determination, protein-ligand/protein-protein complex NMR structure determination, small molecule fragment library screening, and much more…

You may use the form below to
contact us if you have questions about our structural biology services platform.
Maria Håkansson and Raymond Kimbung, protein crystallization facility  at SARomics Biostructures

Latest blog posts

Our blog provides the latest company updates, an overview of the latest publications, and general posts discussing various aspects of structural biology, structure-based lead discovery, and drug design. Older news can be found in our news archive, and a list of recent publications on our publications page.
Compound library screening in drug discovery aims to identify a compound or a series of compounds that can bind to the drug target and modulate its activity. Here, we discuss weak affinity chromatography (WAC™), the proprietary fragment screening technique jointly owned by SARomics Biostructures and Red Glead Discovery.
Read more…
This post reviews some highlights of 2023 and shows some representative projects and company business development activities. Three examples within our main areas of expertise: X-ray crystallography, NMR spectroscopy, and integrated drug discovery, are discussed.
Read more…
The third article in our series about therapeutic monoclonal antibodies focuses on structural characterization and comparability analysis of biosimilars. We discuss existing evidence that shows that NMR spectroscopy is far superior to other established methods for comparability assessment.
Read more…